Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cymbalta Adds Musculoskeletal Pain Claim Despite Advisory Committee Concerns

This article was originally published in The Pink Sheet Daily

Executive Summary

Label for duloxetine's new use emphasizes that efficacy was shown only in patients with chronic lower back pain and osteoarthritis.
Advertisement

Related Content

Patient Selection For Analgesic Trials To Be Improved Under Public-Private ACTION Initiative
Patient Selection For Analgesic Trials To Be Improved Under Public-Private ACTION Initiative
Chronic Pain Indications Will Be Harder To Come By, FDA Says
Chronic Pain Indications Will Be Harder To Come By, FDA Says
Cymbalta Chronic Pain Label: FDA Expresses Faith In Physicians' Judgment
Cymbalta Could Get "Fairly Narrow Broad Indication" For Pain, FDA's Rappaport Says
Cymbalta Pain Advisory Committee Could Hinge On Hepatotoxicity Warning

Topics

Advertisement
UsernamePublicRestriction

Register

PS071529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel